Antares Pharma Appoints Edward Tykot Senior Vice President, Corporate Development

Return to all news

EWING, N.J., Dec. 10, 2019 (GLOBE NEWSWIRE) -- Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Edward Tykot to the position of Senior Vice President, Corporate Development. Mr. Tykot is a seasoned corporate and business development executive with a proven record of success in both small and large pharmaceutical companies.

Most recently, Mr. Tykot was Vice President, Business Development of Nevakar, Inc. Prior to Nevakar, Ed served as Vice President Business Development and Strategic Planning of Eagle Pharmaceuticals, Inc. where he was responsible for identifying and negotiating strategic opportunities for the organization. Prior to joining Eagle, Mr. Tykot worked at Actavis plc (formerly Watson Pharmaceuticals) from 1995 until 2014. Ed served as Executive Director Global Business Development and Alliance Management from 2010-2014 and Executive Director of Business Development from 2004 until 2010. He was responsible for performing strategic assessments of key therapeutic areas for Actavis’s global brand business. Mr. Tykot identified and screened opportunities, led cross functional due diligence efforts, conducted financial modelling and deal valuation, negotiated and executed deals for both domestic and international markets. Prior to 2004, Mr. Tykot held various roles of increasing responsibility at Watson Pharmaceuticals in the marketing and business development departments. Mr. Tykot started his career at Sandoz. He received his Master’s in Business Administration from New York University and received his Bachelor of Science in Biology from Tufts University.

Robert F. Apple, President and Chief Executive Officer of the Company, stated, “We are very pleased to have an experienced executive like Ed join our leadership team at Antares Pharma. I believe that adding Ed to the Antares team at a time when we are experiencing tremendous growth in our business will have a positive impact on our goal to expand our commercial presence and our pipeline."

About Antares Pharma

Antares Pharma, Inc. is a combination drug device company focused primarily on the development and commercialization of self-administered parenteral pharmaceutical products using advanced drug delivery auto injector technology. The Company has a portfolio of proprietary and partnered commercial products with several product candidates in various stages of development, as well as significant strategic alliances with industry leading pharmaceutical companies including Teva Pharmaceutical Industries, Ltd. (Teva), AMAG Pharmaceuticals, Inc. (AMAG), Pfizer Inc. (Pfizer) and Idorsia Pharmaceuticals Ltd. (Idorsia). Antares Pharma’s proprietary products include XYOSTED® (testosterone enanthate) injection, OTREXUP® (methotrexate) injection for subcutaneous use and Sumatriptan Injection USP, which is distributed by Teva.

SAFE HARBOR STATEMENT UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995

This press release contains forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Forward-looking statements are subject to certain risks and uncertainties that can cause actual results to differ materially from those described. Factors that may cause such differences include, but are not limited to: future successful corporate development transactions, market acceptance, adequate reimbursement coverage and commercial success of XYOSTED® and future revenue from the same; successful development including the timing and results of the clinical bridging and Phase 3 clinical trial of the drug device combination product for Selatogrel with Idorsia Pharmaceuticals and FDA and global regulatory approvals and future revenue from the same; market acceptance of Teva’s generic epinephrine auto-injector product and future revenue from the same; our expectations regarding whether the FDA will pursue withdrawal of approval for AMAG Pharmaceuticals Inc.’s Makena® subcutaneous auto injector following the recent FDA advisory committee meeting and future prescriptions, market acceptance and revenue from Makena® subcutaneous auto injector; Teva’s ability to successfully commercialize VIBEX® Sumatriptan Injection USP and the amount of revenue from the same; continued growth of prescriptions and sales of OTREXUP®; the timing and results of the Company’s or its partners’ research projects or clinical trials of product candidates in development; actions by the FDA or other regulatory agencies with respect to the Company’s products or product candidates of its partners; continued growth in product, development, licensing and royalty revenue; achievement of the 2019 revised revenue guidance; the Company’s ability to meet loan extension and interest only payment milestones and the ability to repay the debt obligation to Hercules Capital; the Company’s ability to obtain financial and other resources for its research, development, clinical, and commercial activities and other statements regarding matters that are not historical facts, and involve predictions. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results, performance, achievements or prospects to be materially different from any future results, performance, achievements or prospects expressed in or implied by such forward-looking statements. In some cases you can identify forward-looking statements by terminology such as ''may'', ''will'', ''should'', ''would'', ''expect'', ''intend'', ''plan'', ''anticipate'', ''believe'', ''estimate'', ''predict'', ''potential'', ''seem'', ''seek'', ''future'', ''continue'', or ''appear'' or the negative of these terms or similar expressions, although not all forward-looking statements contain these identifying words. Additional information concerning these and other factors that may cause actual results to differ materially from those anticipated in the forward-looking statements is contained in the "Risk Factors" section of the Company's Annual Report on Form 10-K, and in the Company's other periodic reports and filings with the Securities and Exchange Commission. The Company cautions investors not to place undue reliance on the forward-looking statements contained in this press release. All forward-looking statements are based on information currently available to the Company on the date hereof, and the Company undertakes no obligation to revise or update these forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law.

Investor Contacts:

Jack Howarth
Vice President, Corporate Affairs
(609) 359-3016
jhowarth@antarespharma.com

By: GlobenewsWire - 10 Dec 2019
Return to all news

Explore our database of over 50,000 companies